News Servier gets a win for cancer drug Tibsovo, bought in $1.8bn... Just three months after completing its $1.8 billion takeover of Agios' oncology pipeline, Servier has reported pos
News Sanofi’s rare disease drug Cablivi approved in the EU The European Commission has approved Sanofi’s Cablivi, the first treatment for patients with the rare blood-clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which is
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face